Seeking Alpha

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after...

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after its marketing website inadvertently circulated a report that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged the error, saying that says no determination on AMR101 NDA has yet been made by the FDA, adding that information on the site was outdated and should not be relied on.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)